GSK to cut up to 1,217 jobs in Belgium as cost-saving plan accelerates

GSK announced it will lay off up to 1,217 employees in Belgium as part of its global cost-saving program.

The cuts will affect R&D, manufacturing and support functions across the company's three main vaccine sites in Gemboux, Wavre and Rixensart.

The restructuring is intended to address over-capacity in the vaccine supply chain and to redirect resources toward priority pipeline projects, supporting the “accelerating growth” strategy that aims for £1.9 billion of annual savings by 2029.